At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 33 enrolled
Drug / intervention
VIR-3434 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Platform Study Evaluating the Efficacy and Safety of Investigational Therapies in Participants With Chronic Hepatitis B Infection (PREVAIL)
In Brief
A Phase 2 clinical trial evaluating VIR-3434, VIR-2218, and 2 other interventions for Hepatitis B, Chronic. Completed, enrolled 33 participants across 15 sites in 6 countries.
Detailed Summary
This is a Phase 1b/2 platform study framework to evaluate the safety and efficacy of investigational candidate(s) and their combinations as potential treatments for adults with chronic hepatitis B virus infection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis B, Chronic
CountriesFrance, Hong Kong, Moldova, Romania, South Korea, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedNov 2022
Enrollment StartMay 2023
Primary CompletionOct 2024
Study CompletionAug 2025
TodayJul 2026
First PostedNov 10, 2022
Enrollment StartMay 10, 2023
Primary CompletionOct 15, 2024
Study CompletionAug 19, 2025
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 3.6 years ago
Interventions
VIR-3434drug
VIR-3434 given by subcutaneous injection
VIR-2218drug
VIR-2218 given by subcutaneous injection
TDFdrug
TDF given orally
PEG-IFNαdrug
PEG-IFNα given by subcutaneous injection